Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC

Inclusion Criteria: * Man or woman \> 18 years of age * Competent to comprehend, sign, and date an IEC-approved informed consent form * Histologically or cytologically-confirmed metastatic adenocarcinoma of the colon or rectum. * Radiographically documented disease progression per modified RECIST criteria either while receiving or ≤ 6 months after the last dose of prior first-line chemotherapy for mCRC * At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST criteria. * If subject has prior history of cancer other than colorectal carcinoma, basal cell carcinoma, or cervical carcinoma in situ, then subject must not have had treatment or active disease within 5 years. * Prior radiotherapy is acceptable. * One and only one prior chemotherapy regimen for mCRC consisting of first-line fluoropyrimidine-based chemotherapy. * ECOG performance status of 0, 1 or 2 * Life expectancy ≥ 3 months * Hematologic function:ANC \> 1.5 x 109/L, Platelet count \> 100 x 109/L, Hemoglobin \> 10 g/dL * Renal function: Creatinine \< 1.5 mg/dL * Hepatic function: AST and ALT \< 3 x ULN (if liver metastases \< 5 x ULN) * Bilirubin \< 2 x ULN Exclusion Criteria: * No more than one prior chemotherapy regimen for mCRC consisting of first-line fluoropyrimidine-based chemotherapy. (Prior adjuvant fluoropyrimidine-based chemotherapy is allowed) * Prior systemic therapy for the treatment of metastatic colorectal carcinoma with the exception of adjuvant fluoropyrimidine-based chemotherapy given at least 6 months prior to enrolment. * Systemic chemotherapy, hormonal therapy, immunotherapy or experimental or approved proteins/antibodies (eg, bevacizumab) ≤ 30 days before inclusion * Unresolved toxicities from prior systemic therapy that, in the opinion of the investigator, does not qualify the patient for inclusion * Central nervous system/brain metastases * Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment or a history of ventricular arrhythmia * Prior anti-EGFr antibody therapy (eg, cetuximab) or treatment small molecule EGFr tyrosine kinase inhibitors (eg, erlotinib) * History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest CT scan * Treatment for systemic infection within 14 days before initiating study treatment * Radiotherapy ≤ 14 days prior to inclusion. Patients must have recovered from all radiotherapy-related toxicities * Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as \> 4 loose stools per day) * History of Gilbert's syndrome or dihydropyrimidine deficiency * History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results * Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection * subject allergic to the ingredients of the study medication or to Staphylococcus protein A * Any co-morbid disease that would increase risk of toxicity * Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures * Any investigational agent within 30 days before enrolment * Must not have had a major surgical procedure within 28 days of randomization * Subject who is pregnant or breast feeding * Woman or man of childbearing potential not consenting to use adequate contraceptive precautions i.e. double barrier contraceptive methods * Subject unwilling or unable to comply with study requirements